Arvinas (ARVN) Cash & Current Investments (2017 - 2026)
Arvinas' (ARVN) quarterly Cash & Current Investments came in at $614.9 million in Q1 2026, down 35.57% year-on-year from $954.3 million in Q1 2025, and down 10.29% quarter-over-quarter from $685.4 million in Q4 2025.
Arvinas (ARVN) Cash & Current Investments (2017 - 2026) Analysis & Trends
Arvinas' Cash & Current Investments history runs 10 years deep, the most recent figure standing at $614.9 million for Q1 2026.
- On a quarterly basis, Cash & Current Investments fell 35.57% year-over-year to $614.9 million in Q1 2026; TTM through Mar 2026 was $614.9 million, a 35.57% decrease from a year earlier, with the FY2025 full-year figure at $685.4 million, down 34.06% from the prior year.
- Cash & Current Investments retreated to $614.9 million in Q1 2026 per ARVN's latest filing, from $685.4 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $1.2 billion in Q1 2024 and bottomed at $66.8 million in Q1 2022.
- The 5-year median for Cash & Current Investments is $160.3 million (2024), against an average of $436.2 million.
- Across the five-year window, Cash & Current Investments sank 91.06% in 2022 and surged 824.41% in 2025, its largest moves.
- Year by year, Cash & Current Investments stood at $86.8 million in 2022, then jumped by 265.44% to $317.2 million in 2023, then jumped by 227.68% to $1.0 billion in 2024, then slumped by 34.06% to $685.4 million in 2025, then retreated by 10.29% to $614.9 million in 2026.
- Per Business Quant, the three latest ARVN Cash & Current Investments figures stand at $614.9 million (Q1 2026), $685.4 million (Q4 2025), and $787.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.27 Bn | 467.47 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 122.18 Bn | 114.93 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.32 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Arvinas | 531.20 Mn | -83.70 Mn | - | 614.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 614.90 Mn |
| Dec 31, 2025 | 685.40 Mn |
| Sep 30, 2025 | 787.60 Mn |
| Jun 30, 2025 | 861.20 Mn |
| Mar 31, 2025 | 954.30 Mn |
| Dec 31, 2024 | 1.04 Bn |
| Sep 30, 2024 | 85.20 Mn |
| Jun 30, 2024 | 160.30 Mn |
| Mar 31, 2024 | 1.17 Bn |
| Dec 31, 2023 | 317.20 Mn |
| Sep 30, 2023 | 119.20 Mn |
| Jun 30, 2023 | 96.10 Mn |
| Mar 31, 2023 | 135.70 Mn |
| Dec 31, 2022 | 86.80 Mn |
| Sep 30, 2022 | 138.10 Mn |
| Jun 30, 2022 | 97.70 Mn |
| Mar 31, 2022 | 66.80 Mn |
| Dec 31, 2021 | 112.80 Mn |
| Sep 30, 2021 | 1.54 Bn |
| Jun 30, 2021 | 53.23 Mn |